tetano
Editor, Senior Moderator
Dose Response
. 2020 Aug 14;18(3):1559325820949740.
doi: 10.1177/1559325820949740. eCollection Jul-Sep 2020.
Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China
Xingsheng Hu[SUP] 1 2 [/SUP], Chunhong Hu[SUP] 1 2 [/SUP], Ping Zhong[SUP] 3 [/SUP], Yajing Wen[SUP] 4 [/SUP], Yong Yang[SUP] 5 [/SUP], Juan Chen[SUP] 6 [/SUP], Xiangyu Chen[SUP] 7 [/SUP]
Affiliations
Abstract
Objective: To compare the efficacy of 3/4-drugs' group with 1-drug's or 2-drugs' groups in coronavirus disease 2019 (COVID-19).
Methods: We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.
Results: The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug's or 2-drugs' groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug's or 2-drugs' groups (both were 9 days) (P < 0.001). The patients' discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug's or 2 drugs' group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05).
Conclusion: The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients'discharge.
Keywords: COVID-19; antiviral drugs; length of hospitalization; virus clearance time.
. 2020 Aug 14;18(3):1559325820949740.
doi: 10.1177/1559325820949740. eCollection Jul-Sep 2020.
Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China
Xingsheng Hu[SUP] 1 2 [/SUP], Chunhong Hu[SUP] 1 2 [/SUP], Ping Zhong[SUP] 3 [/SUP], Yajing Wen[SUP] 4 [/SUP], Yong Yang[SUP] 5 [/SUP], Juan Chen[SUP] 6 [/SUP], Xiangyu Chen[SUP] 7 [/SUP]
Affiliations
- PMID: 32855629
- PMCID: PMC7429915
- DOI: 10.1177/1559325820949740
Abstract
Objective: To compare the efficacy of 3/4-drugs' group with 1-drug's or 2-drugs' groups in coronavirus disease 2019 (COVID-19).
Methods: We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.
Results: The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug's or 2-drugs' groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug's or 2-drugs' groups (both were 9 days) (P < 0.001). The patients' discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug's or 2 drugs' group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05).
Conclusion: The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients'discharge.
Keywords: COVID-19; antiviral drugs; length of hospitalization; virus clearance time.